CL2015002171A1 - Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. - Google Patents

Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.

Info

Publication number
CL2015002171A1
CL2015002171A1 CL2015002171A CL2015002171A CL2015002171A1 CL 2015002171 A1 CL2015002171 A1 CL 2015002171A1 CL 2015002171 A CL2015002171 A CL 2015002171A CL 2015002171 A CL2015002171 A CL 2015002171A CL 2015002171 A1 CL2015002171 A1 CL 2015002171A1
Authority
CL
Chile
Prior art keywords
methods
ferric pyrophosphate
soluble ferric
treating iron
difficulty
Prior art date
Application number
CL2015002171A
Other languages
English (en)
Inventor
Ajay Gupta
Original Assignee
Charak Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50097899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charak Llc filed Critical Charak Llc
Publication of CL2015002171A1 publication Critical patent/CL2015002171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)

Abstract

UN METODO DE TRATAMIENTO DE LA DEFICIENCIA DE HIERRO QUE REDUCE O ELIMINA LA DOSIS DE UN AGENTE ESTIMULANTE DE LA ERITROPOYESIS (AEE) PARA LOGRAR O MANTENER LOS NIVELES DE HEMOGLOBINA OBJETIVO, QUE COMPRENDE EL USO DE UNA COMPOSICION DE PIROFOSFATO FERRICO SOLUBLE Y POSTERIOR USO DE UN AEE.
CL2015002171A 2013-02-01 2015-08-03 Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. CL2015002171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361759531P 2013-02-01 2013-02-01

Publications (1)

Publication Number Publication Date
CL2015002171A1 true CL2015002171A1 (es) 2016-02-05

Family

ID=50097899

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002171A CL2015002171A1 (es) 2013-02-01 2015-08-03 Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.

Country Status (20)

Country Link
US (3) US20150366907A1 (es)
EP (2) EP3789034A1 (es)
JP (3) JP2016507527A (es)
KR (1) KR102236714B1 (es)
CN (2) CN104936609B (es)
AU (3) AU2014212127A1 (es)
BR (1) BR112015018549A8 (es)
CA (1) CA2900043A1 (es)
CL (1) CL2015002171A1 (es)
EA (1) EA032407B1 (es)
HK (1) HK1215185A1 (es)
IL (1) IL240257A0 (es)
MX (1) MX370139B (es)
NI (1) NI201500100A (es)
PE (1) PE20151751A1 (es)
PH (1) PH12015501708A1 (es)
SG (1) SG11201506022VA (es)
TW (1) TW201517913A (es)
WO (1) WO2014121155A1 (es)
ZA (1) ZA201506364B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3398656B1 (en) 2012-06-15 2023-01-11 Symrise AG Compositions comprising hyaluronan biosynthesis promoting agents
US20160250254A1 (en) * 2013-11-05 2016-09-01 Rockwell Medical, Inc. Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
KR20180050346A (ko) * 2015-09-04 2018-05-14 락웰 메디컬, 인코포레이티드 가용성 고체 피로인산제2철(Soluble Ferric Pyrophosphate) 제제, 키트 및 이를 사용하는 방법
CN106581053A (zh) * 2015-10-20 2017-04-26 华仁药业股份有限公司 一种具有补铁功能的腹膜透析液
EP3842808A4 (en) * 2018-08-24 2022-05-18 National University Corporation Yokohama National University ADMINISTRATION MANAGEMENT APPARATUS, ADMINISTRATION MANAGEMENT METHOD AND PROGRAM
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
US20230083600A1 (en) * 2020-02-11 2023-03-16 Quest Diagnostics Investments Llc System for determining an underlying cause of anemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
JP3955639B2 (ja) * 1996-12-31 2007-08-08 グプタ，アジャイ 血液透析及び腹膜透析患者における鉄デリバリーのための方法及び医薬組成物
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6779648B2 (en) * 2000-07-13 2004-08-24 Psi Sales, Inc. 360 Degree rotatable lifter arm for log singulator
JP2005068055A (ja) * 2003-08-22 2005-03-17 Fujiyakuhin Co Ltd 無機元素含有水性コロイド分散液
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
BRPI0620425B8 (pt) * 2005-12-23 2021-06-22 Gupta Ajay composição para nutrição parenteral, método para preparar a mesma, uso, e, kit
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
BR112013017169A2 (pt) * 2011-01-07 2016-10-04 Merrion Res Iii Ltd composições farmacêuticas de ferro para administração oral

Also Published As

Publication number Publication date
EA032407B1 (ru) 2019-05-31
CN104936609A (zh) 2015-09-23
IL240257A0 (en) 2015-09-24
EP2950806A1 (en) 2015-12-09
US20180280432A1 (en) 2018-10-04
AU2018278891A1 (en) 2019-01-03
ZA201506364B (en) 2022-07-27
EP2950806B1 (en) 2020-07-15
EP3789034A1 (en) 2021-03-10
CN104936609B (zh) 2017-04-12
EA201591424A1 (ru) 2015-12-30
WO2014121155A1 (en) 2014-08-07
US20200276232A1 (en) 2020-09-03
PE20151751A1 (es) 2015-12-03
AU2020286223A1 (en) 2021-01-07
JP2016507527A (ja) 2016-03-10
BR112015018549A2 (pt) 2017-07-18
NI201500100A (es) 2019-05-07
AU2014212127A1 (en) 2015-08-20
BR112015018549A8 (pt) 2018-01-30
PH12015501708A1 (en) 2015-10-12
HK1215185A1 (zh) 2016-08-19
KR102236714B1 (ko) 2021-04-06
US20150366907A1 (en) 2015-12-24
AU2018278891B2 (en) 2020-09-10
SG11201506022VA (en) 2015-08-28
JP2019151669A (ja) 2019-09-12
JP2021169525A (ja) 2021-10-28
KR20160004257A (ko) 2016-01-12
CA2900043A1 (en) 2014-08-07
NZ710691A (en) 2020-09-25
MX2015009968A (es) 2016-03-11
TW201517913A (zh) 2015-05-16
CN107007624A (zh) 2017-08-04
MX370139B (es) 2019-12-03

Similar Documents

Publication Publication Date Title
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016000354A1 (es) Modulación de la inmunidad tumoral
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
NI201500118A (es) Imidazopiridazinas sustituidas
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
ECSP14011792A (es) Inhibidores de iap
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2015014344A (es) Terapia contra el cancer.
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА